Lake Street Maintains Buy on AVITA Medical, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Lake Street analyst Brooks O'Neil maintains a 'Buy' rating on AVITA Medical (NASDAQ:RCEL) and raises the price target from $30 to $40.
July 13, 2023 | 3:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AVITA Medical's price target has been raised from $30 to $40 by Lake Street, maintaining a 'Buy' rating.
The news of a price target increase and maintained 'Buy' rating by a reputable analyst is likely to have a positive impact on AVITA Medical's stock in the short term. Investors may see this as a sign of the company's strong potential, leading to increased demand for the stock and potentially driving the price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100